European Journal of Cancer
Volume 41, Issue 6 , Pages 932-940 , April 2005

Prostate cancer metastases to bone: Pathophysiology, pain management, and the promise of targeted therapy

Received 31 August 2004 ,Accepted 2 December 2004.

References 

  1. Ikeda I, Miura T, Konde I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Brit J Urol. 1996;77:102–106
  2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–573
  3. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl):1588–1594
  4. Orr FW, Lee J, Duivenvoorden WCM, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer. 2000;88(Suppl):2912–2918
  5. Hauschka PV, Mavrakos AE, Iafrati MD, et al. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem. 1986;261:12665–12674
  6. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature. 2002;2:584–593
  7. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149–156
  8. Coussens LM, Fingleton B, Matrisian LM. Matrix metallopreoteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–2392
  9. Sledge GW, Qulali M, Goulet R, et al. Effect of matrix metallopreoteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst. 1995;87:1546–1550
  10. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine b16-f10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst. 1994;86:299–304
  11. Thalmann G, Anezinis P, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577–2581
  12. Kostenuik PJ, Singh G, Orr FW. Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis. 1997;15:41–52
  13. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80(Suppl):1581–1587
  14. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 2004;64:994–999
  15. Guise TA, Yin JJ, Mohammad KS. Role of Endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97(Suppl):779–784
  16. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–668
  17. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvarie. Biochem Biophys Res Commun. 1990;170:998–1005
  18. Yin JJ, et al. Endothelin A receptor blockade inhibits osteoblastic metastases. J Bone Min Res. 2000;15(Suppl 1):1254
  19. Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer. 1983;51:918–924
  20. Kurihara N, Bertolini D, Suda T, et al. Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol. 1990;144:4226–4230
  21. Shariat SF, Andrews B, Kattan WM, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58:1008–1015
  22. Coleman RE, Vinholes J, Abbey ME, Purohit OP. Double blind randomized trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc ASCO. 1996;15:528
  23. Iwamura M, di Sant’Agnese PA, Wu G, et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res. 2003;53:1724–1726
  24. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol. 1996;156:526–531
  25. Roodman GD. Mechanisms of bone metastases. New Engl J Med. 2004;350:1655–1664
  26. Oyajobi BO, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor-κB-IgG-Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572–2578
  27. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res. 2001;61:6372–6376
  28. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, et al. Animal models of bone metastasis. Cancer. 2003;97(Suppl):748–757
  29. Pollard M, Wolter WR, Sun L. Prostate-seminal vesicle cancers induced in noble rats. Prostate. 2000;43:71–74
  30. Stephenson RA, Dinney CPN, Gohji K, et al. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst. 1992;84:951
  31. Achibarou A, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994;54:2372–2377
  32. Tsingotjidou AS, Zotalis G, Jackson KR, et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res. 2001;21:971–978
  33. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology. 1999;3:1537–1549
  34. Oremek GM, Weis A, Sapoutzis N, Sauer-Eppel H. Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res. 2003;23:987–990
  35. Pelger RC, Hamdy NA, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998;22:403–408
  36. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80:1595–1607
  37. Pollen JJ, Gerber K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate. Cancer. 1981;47:2585
  38. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-fluoro-d-glucose. Radiology. 1996;199:751–756
  39. Hanna SL, Fletcher BD, Fairclough DL, et al. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol. 1991;20:79–84
  40. Payne R. Mechanisms and management of bone pain. Cancer. 1997;80:1608–1613
  41. McNicol E, Strassels S, Goudas L, et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids for cancer pain: a systematic review. J Clin Oncol. 2004;22:1975–1992
  42. Tong D, Gillick KL, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the radiation therapy oncology group. Cancer. 1982;50:893–899
  43. Price P, Hoskin PJ, Easton D, et al. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247–255
  44. Arcangeli G, Micheli A, Arcangeli G, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol. 1989;14:95–101
  45. Smith MR, Kaufman DS. Management of bone metastases: external beam radiation therapy, radiopharmaceuticals, and bisphosphonates. In:  Kantoff PW,  Carroll PK,  D’Amico AV editor. Prostate cancer principles and practice. Philadelphia: Lippincott Williams and Wilkins; 2002;p. 595–601
  46. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9:2394–2399
  47. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882
  48. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004;171:1537–1542
  49. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. 1997;80(8 suppl):1652–1660
  50. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997;57:3890–3894
  51. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998;339:398–400
  52. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–363
  53. Sun YC, Geldof AA, Newling DW, et al. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol. 1992;148:1270–1273
  54. Mertens WC, Filipczak LA, Ben-Josef E, et al. Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. CA Cancer J Clin. 1998;48:361–374
  55. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519–526
  56. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylendediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926–1931
  57. Robson M, Dawson N. How is androgen dependent metastatic prostate cancer best treated?. Hematol Oncol Clin North Am. 1996;10:727–747
  58. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335–3342
  59. Petrylak DP, Tangen C, Hussain M, et al. SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA. Proc Am Soc Clin Oncol. 2004;23:2;(abstr 3)
  60. Eisenberger MA, Dewit R, Berg W, et al. A multicenter phase III comparison of docetaxel (D)+prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone refractory prostate cancer. In: Proceedings of ASCO 2004. p. 23; Abstract #4
  61. Brown HK, Healey JH. Metastatic cancer to the bone. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles & practice of oncology. Philadelphia: Lippincott Williams and Wilkins; 2001;p. 2713–2729
  62. Patchell R, Tibbs PA, Regine WF, et al. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis. Proc Am Soc Clin Oncol. 2003;22:21;(abstr 2).
  63. Flynn DF, Shipley WU. Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am. 1991;18:145
  64. Sorenson PS, Borgesen SE, Rohde K, et al. Metastatic epidural spinal cord compression. Cancer. 1990;65:1502–1509
  65. Hortobayagi GN. Novel approaches to the management of bone metastases. Semin Oncol. 2003;30(Suppl 16):161–166
  66. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689
  67. Carducci JBN, Saad F, et al. Effects of atrasentan on disease progression and biologic markers in men with metastatic hormone refractory prostate cancer: phase III study. Proc. ASCO. 2004;23;Abstract # 4508.
  68. Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun. 1994;199:380–386
  69. Pinski J, Weeraratna A, Uzgare AR, et al. Trk receptor induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res. 2002;62:986–989

PII: S0959-8049(05)00048-1

doi: 10.1016/j.ejca.2004.12.026

European Journal of Cancer
Volume 41, Issue 6 , Pages 932-940 , April 2005

Article Tools

* Image Usage & Resolution